US Stocks Dragon and Tiger News: VISTA halts trials to seek sale, once-a-year weight loss drug rises 270% in one day

New data progress: PSMA/CD3 pro-antibody JANX007 is in the interim clinical data of Phase 1 treatment of mCRPC, and EGFR/CD3 pro-antibody JANX008 is in the interim data of Phase 1 treatment of solid tumors; GLP-1/GIP receptor agonist VK2735 Phase 2 VENTURE trial results in obese patients; ERK/NFκB inhibitor NE3107 announced PD (Parkinson's disease) Phase 2a data and AD (Alzheimer's disease) Phase 3 data; KIT monoclonal antibody Barzolvolimab treatment of CSU Phase 2 12-week results; CD45 iodine RDC Iomab-B is in Phase 3 treatment of AML, and announced Phase 3 SIERRA trial results.

On February 26, 2024, Janux disclosed the interim clinical data of PSMA/CD3 pro-antibody JANX007 in Phase 1 treatment of mCRPC, and the interim data of EGFR/CD3 pro-antibody JANX008 in Phase 1 treatment of solid tumors.

● Emerging data from JANX007 demonstrates a potential best-in-class profile: good efficacy and safety in heavily pretreated advanced mCRPC subjects

● 83% (5/6) of subjects achieved a PSA50 decline at the first dose ≥ 0.2mg

● 56% (10/18) of subjects achieved a PSA50 decline at the first dose ≥ 0.1mg

● No CRS greater than grade 2 was observed in any cohort

● Early JANX008 data showed differentiated safety and encouraging signs of efficacy in heavily pretreated subjects with different solid tumor types

● 1 NSCLC subject met RECIST PR, which was still maintained at the 18th week of treatment, with 100% reduction in lung target lesions, disappearance of liver metastases, and no CRS or TRAEs

●No CRS greater than grade 1 was observed in any cohort

●No SAEs or DLTs related to treatment have been observed

Author: Fengshuo Ventures

Link: https://xueqiu.com/7742989740/292173736

Source: Xueqiu

Copyright belongs to the author. For commercial reprint, please contact the author for authorization, and for non-commercial reprint, please indicate the source.

Risk warning: The views mentioned in this article represent only personal opinions, and the targets involved are not recommended. Buying and selling based on this is at your own risk.